Table 1 Demographics and clinical characteristics at baseline
From: Prevalence and predictors of non-alcoholic liver disease on MRI among patients with Crohn's disease
Non-NAFLD | NAFLD | P-value | |
|---|---|---|---|
(n = 257) | (n = 83) | ||
Gender (M, %) | 178(69.3) | 64(77.1) | 0.21 |
Age, year | 30 ± 11 | 32 ± 11 | 0.07 |
BMI, kg/m2 | 19.6 ± 2.7 | 22.3 ± 4.5 | < 0.01 |
Current smoker | 9(3.5) | 2(2.4) | 1 |
MS | 18(7) | 29(34.9) | < 0.01 |
Disease duration, year | 2(0.8–5) | 4(1–7) | 0.01 |
CDAI | 134(73–251) | 130(65–246) | 0.57 |
Active CD | 125(48.6) | 36(43.4) | 0.45 |
Disease location | |||
L1 | 98(38.1) | 38(45.8) | 0.25 |
L2 | 11(4.3) | 4(4.8) | 0.77 |
L3 | 148(57.6) | 41(49.4) | 0.37 |
P | 161(62.6) | 49(59) | 0.6 |
Disease Behavior | |||
B1 | 150(58.4) | 42(50.6) | - |
B2 | 61(23.7) | 25(30.1) | - |
B3 | 46(17.9) | 16(19.3) | 0.4 |
CRP | 0.6(0.5–5.6) | 0.6(0.5–5.3) | 0.72 |
Alb | 46.7(41.8–50.2) | 46.1(42.9–49.3) | 0.98 |
PAB | 220(166.5–263) | 256(197.1–292.9) | < 0.01 |
ALT | 14(10–22) | 23.8(16–36) | < 0.01 |
AST | 18(15–22) | 22(17–27) | < 0.01 |
GGT | 16(12.4–23) | 26(15–41) | < 0.01 |
5-ASA | 146(56.8) | 49(59) | 0.63 |
AZA | 107(41.7) | 41(49.4) | 0.06 |
Corticosteroids | 96(37.4) | 38(45.8) | 0.04 |
Prolonged anti-TNF-α antibody use | 151(58.8) | 51(61.4) | 0.7 |
TNF-α (ELISA) | 272.7 ± 320.8 | 222.9 ± 303.1 | 0.59 |
IL-6(ELISA) | 5.3 ± 4.3 | 4.3 ± 2.8 | 0.39 |